Dr. Rao on the SOFT Trial in Patients With Premenopausal Breast Cancer

Ruta D. Rao, MD
Published: Tuesday, Mar 20, 2018



Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.

Updated results from the SOFT trial presented by Gini F. Fleming, MD, showed that the addition of ovarian suppression benefited patients with premenopausal breast cancer. The trial enrolled approximately 3000 patients who were randomized into 1 of 3 arms. Patients were randomized to either tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression.

The analysis compared tamoxifen with tamoxifen plus ovarian suppression and found that there was a significantly improved disease-free survival for these patients. This was especially true in the patients who had received prior chemotherapy, notes Rao.
 


Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.

Updated results from the SOFT trial presented by Gini F. Fleming, MD, showed that the addition of ovarian suppression benefited patients with premenopausal breast cancer. The trial enrolled approximately 3000 patients who were randomized into 1 of 3 arms. Patients were randomized to either tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression.

The analysis compared tamoxifen with tamoxifen plus ovarian suppression and found that there was a significantly improved disease-free survival for these patients. This was especially true in the patients who had received prior chemotherapy, notes Rao.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x